Cenplacel-L

Drug Profile

Cenplacel-L

Alternative Names: PDA-001; PDAC cells - Celgene Cellular Therapeutics; Placental-derived adherent cells intravenous

Latest Information Update: 05 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celgene Cellular Therapeutics
  • Class Antirheumatics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease
  • No development reported Amyotrophic lateral sclerosis; Cancer; Graft-versus-host disease; Haematological disorders; Multiple sclerosis; Neuropathic pain; Rheumatoid arthritis; Ulcerative colitis
  • Discontinued Pulmonary sarcoidosis; Stroke

Most Recent Events

  • 05 Oct 2015 No recent reports on development identified - Phase-I for Haematological disorders in USA (IV)
  • 05 Oct 2015 No recent reports on development identified - Preclinical for Amyotrophic lateral sclerosis in USA (IV)
  • 05 Oct 2015 No recent reports on development identified - Preclinical for Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top